1- World Health Organization. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. WHO technical report series. Geneva : WHO, 1994
2- Meunier PJ. Progrès dans le diagnostic et la prise en charge. Martin Dunitz, Londres, 1999
3- Comment prévenir les fractures dues à l’ostéoporose ? HAS fiche de synthèse mai 2007. www.has-sante.fr
4- Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate in chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 1999:18 ; 266-7
5- Legroux-Gérot I, Chastanet P, Cotten A et al. Indications de la vertébroplastie : fractures vertébrales ostéoporotiques. Réfléxions Rhumatologiques. 2003 ; 60(7) :13-6
6- Cyteval C. Essais randomisés de la vertébroplastie pour le traitement de la douleur des fractures vertébrales par insuffisance. J Radiol2009 ; 90 : 1785-6
7- Cyteval C. Suivi prospectif du risque fracturaire après vertébroplastie utilisant un faible volume de ciment chez des patients ostéoporotiques. J Radiol 2008 ; 89 : 797-801
8- Malliopoulos X. Tassement vertébral ostéoporotique algique : prise en charge rééducative. Réfléxions Rhumatologiques 2000 ; 27(4) :20-3
9- Liberman UA, Weiss SR, Bröll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med1995 ; 333 : 1437-43
10- Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996 ; 348 : 1535-41
11- Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis : A randomized controlled trial. JAMA 1999 ; 282 : 1344-52
12- Reginster J, Minne HW, Sorenson OH et al ; Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int2000 ; 11 : 83-91
13- Boonen S, McClung MR, Eastell R et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older : implications for the use of antiresorptive agents in the old and oldest old.J Am Geriatr Soc 2004 ; 52 : 1832-39
14- Chesnut CH III, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004 ; 19 : 1241-9
15- Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis ; N Engl J med 2007 ; 356 : 1809-22
16- Woo SB, Hellstein JW, Kalmar JR. Bisphosphonates and osteonecrosis of the jaws. Ann Int Med 2006 ; 144 : 753-61
17- Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifène : results from a 3-year randomized clinical trial.JAMA 1999 ; 282 : 637-45
18- Cummings SR, San Martin J, Mc Clung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med2009 ; 361 : 756-65
19- Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001 ; 344 : 1434-41
20- Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004 ;350:459-6
Mise au point
Prise en charge de la goutte en 2025
Mise au point
Le prurit
Mise au point
Les infiltrations en médecine générale
Mise au point
Diagnostic de la maladie d’Alzheimer en 2025